Theravance Biopharma, INC 8-K filings

Theravance Biopharma announced its second quarter 2026 financial results, highlighting an 11% year-over-year increase in YUPELRI collaboration revenue and providing an update on its pending acquisition by Zymeworks.

Theravance Biopharma, Inc. announced a definitive agreement to be acquired by Zymeworks Inc. for $17.00 per share in cash, plus a contingent value right (CVR) for future ampreloxetine proceeds.

Theravance Biopharma shareholders re-elected all director nominees and ratified the appointment of Ernst & Young LLP.

Theravance Biopharma reported Q1 2026 financial results, highlighting YUPELRI revenue growth, successful cost reduction initiatives, and an ongoing strategic review.

Theravance Biopharma and Mylan have settled patent litigation with Mankind Pharma, allowing generic YUPELRI launch in the U.S. from April 23, 2039.

Theravance Biopharma, Inc. reported strong fourth-quarter and full-year 2025 financial results, driven by YUPELRI and TRELEGY sales milestones, while announcing an organizational restructuring following negative ampreloxetine study results.

Theravance Biopharma announced an organizational restructuring and accelerated strategic review following the failure of its Phase 3 CYPRESS study for ampreloxetine.

Theravance Biopharma reports strong Q3 2025 financial performance, driven by YUPELRI sales and anticipated TRELEGY milestones, as it prepares for pivotal Ampreloxetine Phase 3 data in Q1 2026.

Theravance Biopharma hosted a virtual investor event highlighting its investigational drug Ampreloxetine for neurogenic orthostatic hypotension in multiple system atrophy, with Phase 3 data expected in Q1 2026.

Theravance Biopharma reported record third-quarter 2025 YUPELRI net sales and achieved non-GAAP breakeven, while advancing its pivotal Phase 3 CYPRESS study for ampreloxetine with topline results expected in Q1 2026.

Theravance Biopharma announced the completion of enrollment in the open-label portion of its pivotal Phase 3 CYPRESS study for ampreloxetine in patients with symptomatic neurogenic orthostatic hypotension (nOH) due to multiple system atrophy (MSA).

Theravance Biopharma and Mylan have reached a settlement with Cipla, granting a license for a generic YUPELRI version to launch in April 2039.

Theravance Biopharma reports significant Q2 2025 financial improvements driven by YUPELRI sales growth and a $225 million TRELEGY royalty monetization.

Theravance Biopharma, Inc. announced that its partner Viatris, Inc. has received regulatory approval for YUPELRI (revefenacin) in China, leading to a $7.5 million milestone payment and future sales-based royalties.

Theravance Biopharma, Inc. and Mylan have reached a settlement agreement with Eugia Pharma Specialities Ltd., resolving patent litigation related to YUPELRI (revefenacin) inhalation solution and delaying Eugia's generic market entry until April 23, 2039.

Theravance Biopharma, Inc. has announced the sale of its remaining outer-year royalty interest in Trelegy Ellipta to GSK for $225 million in cash, marking the first outcome of its Strategic Review Committee's efforts to maximize shareholder value.

Theravance Biopharma successfully held its 2025 Annual General Meeting, electing Class II directors, ratifying Ernst & Young LLP as its auditor, and approving an advisory resolution on executive compensation.

Theravance Biopharma reports a 6% increase in YUPELRI net sales and progress in ampreloxetine clinical trials in its first quarter 2025 results.

Theravance Biopharma announces strong financial results for Q4 and full year 2024, highlighted by record YUPELRI sales and progress in the CYPRESS study for Ampreloxetine.

Theravance Biopharma announced strong third-quarter 2024 results, highlighted by record YUPELRI sales, and initiated a strategic review to enhance shareholder value.

Theravance Biopharma and Mylan have reached a settlement with Qilu Pharmaceutical, granting them a license to market a generic version of YUPELRI starting April 23, 2039.

Theravance Biopharma presented an investor update, highlighting progress with YUPELRI and ampreloxetine, along with financial guidance and potential milestones.

Theravance Biopharma's second quarter results show a slight decrease in YUPELRI sales, but strong growth in hospital demand, while the CYPRESS trial for ampreloxetine is experiencing enrollment delays.

Theravance Biopharma announced its first quarter 2024 financial results, highlighted by an 18% year-over-year increase in YUPELRI net sales and continued progress in its ampreloxetine clinical program.

Theravance Biopharma's 2024 Annual General Meeting saw the election of Class I directors, ratification of Ernst & Young as auditor, and approval of executive compensation.

Theravance Biopharma and Mylan have reached a settlement with Lupin, granting them a license to market a generic version of YUPELRI starting April 23, 2039, resolving ongoing patent litigation.

Theravance Biopharma achieved non-GAAP profitability in Q4 2023, driven by increased YUPELRI sales and effective expense management, while also advancing its ampreloxetine program.

Theravance Biopharma and Mylan have reached a settlement with Orbicular Pharmaceutical Technologies, granting them a license to market a generic version of YUPELRI starting April 23, 2039.